Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT07168655
- Status
- Completed
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Mavacamten — DRUGAccording to the product label
Study Details
The purpose of this study is to evaluate the real-world outcomes of individuals diagnosed with obstructive hypertrophic cardiomyopathy (oHCM) treated with mavacamten at the Hospital of The University of Pennsylvania in the US
Key Dates
- Start date
- Feb 21, 2023
- Status verified
- Sep 2025
- Primary completion
- Mar 31, 2023
- Completion
- Mar 25, 2025
Study Design
- Enrollment
- 163 participants (actual)
Arms
- Arm: Participants prescribed mavacamten treatment
Primary Outcome Measure
Participant New York Heart Association (NYHA) functional class [ Time Frame: Baseline, and at weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, and 108 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Philadelphia, PA
By research site